Decoy Therapeutics Inc.
Income Statement
| Line Item | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $1.8M | $5.2M | $3.5M | $2.0M | $1.3M | $1.0M | $0 |
| Cost of Revenue | — | — | — | — | $430.8K | $506.5K | $662.7K | $0 |
| Gross Profit | — | — | — | — | $1.5M | $768.0K | $347.9K | $0 |
| Gross Margin | — | — | — | — | 77.9% | 60.3% | 34.4% | — |
| Operating Expenses | ||||||||
| Research & Development | $15.8M | $8.5M | $6.9M | $4.0M | $1.3M | $17.0M | $20.4M | $12.7M |
| SG&A Expense | $7.1M | $6.1M | $6.1M | $7.7M | $2.3M | $18.5M | $19.9M | $16.5M |
| Operating Income | $-31.8M | $-12.8M | $-7.8M | $-8.3M | $-1.7M | $-34.7M | $-39.9M | $-29.2M |
| Operating Margin | — | -696.3% | -148.8% | -238.5% | -86.3% | -2,724.6% | -3,946.5% | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | $-29.2M |
| Income Tax Expense | — | — | — | $0 | — | — | — | — |
| Net Income | $-31.6M | $-12.8M | $-7.4M | $-6.9M | $-1.7M | $-34.4M | $-39.5M | $-29.1M |
| Net Margin | — | -693.8% | -140.5% | -200.2% | -85.6% | -2,701.7% | -3,907.6% | — |
| EPS (Basic) | $-14.88 | $-7.72 | $-0.50 | $-2.12 | $-1.16 | $-1.99 | $-2.43 | $-2.08 |
| EPS (Diluted) | $-14.88 | $-7.72 | $-0.50 | $-2.12 | $-1.16 | $-1.99 | $-2.43 | $-2.08 |
| Shares Outstanding (Basic) | 2.1M | 1.7M | 15.6M | 4.5M | 2.0M | 17.8M | 16.8M | 15.7M |
| Shares Outstanding (Diluted) | 2.1M | 1.7M | 15.6M | 4.5M | 2.0M | 17.8M | 16.8M | 15.7M |
| Dividends Per Share | — | — | — | — | — | — | — | — |